Tuesday, November 24, 2009, 5:26am EST - Canadian Markets open in 4 hours and 4 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Repligen Corp. (RGEN)

 On Nov 23: 4.80 USD   0.00 (0.00%)  
MORE ON RGEN
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Repligen Corporation (NGM:RGEN) Delayed quote dataEdit
Last Trade: 4.80 USD
Trade Time: Nov 23
Change: 0.00 (0.00%)
Prev Close: 4.80
Open: N/A
Bid: N/A
Ask: 5.49 x 500
1y Target Est: 8.00
Day's Range: N/A - N/A
52wk Range: 3.41 - 5.85
Volume: 0
Avg Vol (3m): 80,015.4
Market Cap: 147.64M
P/E (ttm): 3.66
EPS (ttm): 1.31
Div & Yield: N/A (N/A%)
Repligen Corp. (RGEN)
1d  5d  3m  6m  1y  2y  5y  max 
 Add RGEN to Portfolio   Download Data

HEADLINES
• "Black Friday" deals may not signal retail comeback
Reuters (Mon 2:54pm)
• REPLIGEN CORP Financials
EDGAR Online Financials (Wed, Nov 11)
• UPDATE - Regeneron, Sanofi, expand drug partnership
at Reuters (Tue, Nov 10)
• New Star Analyst Rankings for Repligen Corporation
StarMine (Sun, Nov 8)
• Repligen Corp. F2Q09 (Qtr. End 09/30/09) Earnings Call Transcript
at Seeking Alpha (Thu, Nov 5)
• Repligen Q2 Fiscal Year 2010 Earnings Call scheduled for 10:00 am ET today
CCBN (Thu, Nov 5)
• REPLIGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online (Thu, Nov 5)
• Repligen Q2 Fiscal Year 2010 Earnings Release - Before Market Open
CCBN (Thu, Nov 5)
• Repligen Reports Second Quarter Fiscal Year 2010 Financial Results
PRNewswire (Thu, Nov 5)
• Repligen to Present at the Merriman Curhan Ford 6th Annual Investor Summit Tuesday, November 10th, 1:40 p.m. EST
PRNewswire (Tue, Nov 3)
More Headlines for RGEN...
ANALYST
EPS Est (next year) (Mar-08) : N/A
EPS Est (in 2 years) (Mar-09) : N/A
Avg Rec (current)*: 1.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Repligen Corporation, a biopharmaceutical company, engages in the research and development of therapeutics for the treatment of central nervous system diseases.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices